ABSTRACT
Management of non-Hodgkin's lymphomas (NHL) has been significantly changed during last 40 years from radiotherapy to modern polychemotherapy with application of monoclonal antibodies. A ten year experience of the treatment of patients with B-cell NHL with rituximab application was accumulated in National Cancer Institute. The group of patients with NHL, who were treated in oncohematology department in the period from 2001 to 2010, was chosen for study of the efficacy of the treatment with rituximab. The immediate and distant results of the treatment were evaluated in this group of patients. The usage of the polychemotherapy with rituximab was highly efficient in the treatment of primary and relapsed patients with NHL. This group shows high rate of the immediate and distant results of treatment.
Subject(s)
Antibodies, Monoclonal, Murine-Derived/therapeutic use , Antigens, CD20/immunology , Antineoplastic Agents/therapeutic use , B-Lymphocytes/immunology , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/immunology , Secondary Prevention , Adult , Aged , Antibodies, Monoclonal, Murine-Derived/administration & dosage , Antigens, CD20/metabolism , Antineoplastic Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , B-Lymphocytes/cytology , Biopsy , Disease-Free Survival , Drug Administration Schedule , Female , Humans , Longitudinal Studies , Lymphoma, Non-Hodgkin/mortality , Lymphoma, Non-Hodgkin/pathology , Male , Middle Aged , Rituximab , T-Lymphocytes/cytology , T-Lymphocytes/immunology , Treatment Outcome , UkraineABSTRACT
Achievements of world practice about development and prophilaxis of tromboembolic events (VTE) in cancer patients. Particular attention is paid to prevention of VTE in patients with multiply myeloma who receive chemotherapy with Thalidomide.
Subject(s)
Fibrinolytic Agents/administration & dosage , Multiple Myeloma/drug therapy , Thalidomide/adverse effects , Thrombosis/drug therapy , Age Factors , Aspirin/administration & dosage , Aspirin/therapeutic use , Clinical Trials as Topic , Drug Combinations , Enoxaparin/administration & dosage , Enoxaparin/therapeutic use , Fibrinolytic Agents/therapeutic use , Humans , Multiple Myeloma/complications , Multiple Myeloma/physiopathology , Risk Factors , Severity of Illness Index , Thalidomide/administration & dosage , Thalidomide/therapeutic use , Thrombosis/complications , Thrombosis/physiopathology , Warfarin/administration & dosage , Warfarin/therapeutic useABSTRACT
The treatment of patients with refractory forms of Hodgkin's lymphomas in combination with chemo-radiotherapy is priority. Nevertheless, chemotherapy has to include multicomponent schemes and radiation therapy should be an addition and consolidative method to chemotherapy.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hodgkin Disease/drug therapy , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Female , Hodgkin Disease/epidemiology , Hodgkin Disease/pathology , Hodgkin Disease/radiotherapy , Humans , Male , Neoplasm Invasiveness , Neoplasm Staging , Prognosis , Radiotherapy, Adjuvant , Remission Induction , Risk Factors , Young AdultABSTRACT
The results of treatment of patients with multiple myeloma with thalidomide and complications of this treatment are presented. Monotherapy with thalidomide and its combinations with corticosteroids and cytostatics is an effective as first line treatment and as a treatment of patients with refractory disease. The most common side effect is toxic neuropathy. Other complications are less common and are easily controlled with medications.
Subject(s)
Antineoplastic Agents/therapeutic use , Multiple Myeloma/drug therapy , Thalidomide/therapeutic use , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Female , Humans , Male , Middle Aged , Neurotoxicity Syndromes/etiology , Polyneuropathies/chemically induced , Thalidomide/administration & dosage , Thalidomide/adverse effects , Treatment OutcomeABSTRACT
The results of immunophenotyping investigations of periferal blood granulocyte and lymphocyte population, number of p53+ and Bcl-2+ in 57 patients (among them 18 persons suffered after the Chernobyl NPP accident) with chronic phase of chronic myelogenic leukemia were presented in the article. The reduction of CD34+ granulocytes number, normalization of CD95 cells, negative correlation between the number of CD95 and p53, Bcl-2 granulocytes in Imatinib treated patients in comparison with a control group was determined. The results of the investigation confirmed the efficiency of using BCR/ABL tyrosin kinase inhibitor Imatinib in the treatment of chronic phase of CML.
Subject(s)
Antineoplastic Agents/therapeutic use , Apoptosis/drug effects , Granulocytes/drug effects , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Lymphocytes/drug effects , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Adult , Antigens, CD/immunology , Antineoplastic Agents/administration & dosage , Benzamides , Chernobyl Nuclear Accident , Flow Cytometry , Granulocytes/immunology , Granulocytes/pathology , Humans , Imatinib Mesylate , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Lymphocytes/immunology , Lymphocytes/pathology , Middle Aged , Piperazines/administration & dosage , Pyrimidines/administration & dosage , Treatment Outcome , Ukraine , Young AdultABSTRACT
Clinical-and-hematological characteristics are presented of B-cell chronic lymphoid leukosis in those persons who took part in the elimination of the effects of the Chornobyl accident in the remote period. Results are highlighted of treatment of 16 patients with making use of different chemical drug preparations. Employment of fludarabin and cyclophosphan combined in treatment of the medical condition in question has been shown to promote long-term complete and partial remissions in a major proportion of patients, which effect was not achievable with standard means of remediation. A side effect of fludarabin was leukocytopenia that in the presence of changed immunity threatened the patients with development and exacerbation of infections complications. Use of manax and erbisol moderated the immunosuppressive and toxic action of fludarabin, due to which fact infectious complications and drug-induced hepatitis have came to be less common, the patients' quality of life gotten better.
